These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 21667819)

  • 21. [Correlation of somatostatin receptor expression in human hepatocellular carcinoma tissue to serum alpha-fetoprotein concentration].
    Xie YM; Yan LN; Wei B; Guo MM; Tang CW
    Ai Zheng; 2007 Jul; 26(7):688-92. PubMed ID: 17626741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance.
    Silva CB; Ongaratti BR; Trott G; Haag T; Ferreira NP; Leães CG; Pereira-Lima JF; Oliveira Mda C
    Int J Clin Exp Pathol; 2015; 8(10):13185-92. PubMed ID: 26722517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction.
    Murabe H; Shimatsu A; Ihara C; Mizuta H; Nakamura Y; Nagata I; Kikuchi H; Nakao K
    J Neuroendocrinol; 1996 Aug; 8(8):605-10. PubMed ID: 8866248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of somatostatin and its receptors (sstr2, sstr5) in the contractility of gilt inflamed uterus.
    Jana B; Całka J; Czajkowska M
    Res Vet Sci; 2020 Dec; 133():163-173. PubMed ID: 33002813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas.
    Jaquet P; Ouafik L; Saveanu A; Gunz G; Fina F; Dufour H; Culler MD; Moreau JP; Enjalbert A
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3268-76. PubMed ID: 10487698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis.
    Lequoy M; Desbois-Mouthon C; Wendum D; Gupta V; Blachon JL; Scatton O; Dumont S; Bonnemaire M; Schmidlin F; Rosmorduc O; Fartoux L
    Histopathology; 2017 Feb; 70(3):492-498. PubMed ID: 27391928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
    Wild D; Schmitt JS; Ginj M; Mäcke HR; Bernard BF; Krenning E; De Jong M; Wenger S; Reubi JC
    Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1338-47. PubMed ID: 12937948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
    Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
    J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization.
    Reubi JC; Schaer JC; Waser B; Mengod G
    Cancer Res; 1994 Jul; 54(13):3455-9. PubMed ID: 8012966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Expression of somatostatin receptor reporter gene and its correlation with targeted imaging in vivo for detection of pancreas carcinoma].
    Wang ZZ; Qu W; Wang F; Li Y; Wang SK; Wang JQ
    Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):663-6. PubMed ID: 16438887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1--5 and correlation with receptor protein expression and tumor pathology.
    Kumar U; Grigorakis SI; Watt HL; Sasi R; Snell L; Watson P; Chaudhari S
    Breast Cancer Res Treat; 2005 Jul; 92(2):175-86. PubMed ID: 15986128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A single amino acid substitution in somatostatin receptor subtype 5 increases affinity for somatostatin-14.
    Ozenberger BA; Hadcock JR
    Mol Pharmacol; 1995 Jan; 47(1):82-7. PubMed ID: 7838136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
    Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
    Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR.
    Taboada GF; Luque RM; Neto LV; Machado Ede O; Sbaffi BC; Domingues RC; Marcondes JB; Chimelli LM; Fontes R; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
    Eur J Endocrinol; 2008 Mar; 158(3):295-303. PubMed ID: 18299461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies.
    Chinezu L; Vasiljevic A; Jouanneau E; François P; Borda A; Trouillas J; Raverot G
    Hum Pathol; 2014 Jan; 45(1):71-7. PubMed ID: 24182563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological Characterization of Veldoreotide as a Somatostatin Receptor 4 Agonist.
    Dasgupta P; Gűnther T; Schulz S
    Life (Basel); 2021 Oct; 11(10):. PubMed ID: 34685446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors.
    Forssell-Aronsson EB; Nilsson O; Bejegård SA; Kölby L; Bernhardt P; Mölne J; Hashemi SH; Wängberg B; Tisell LE; Ahlman H
    J Nucl Med; 2000 Apr; 41(4):636-42. PubMed ID: 10768564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of somatostatin receptor subtype 2 in growth hormone-secreting pituitary adenoma and the regulation of miR-185.
    Fan X; Mao Z; He D; Liao C; Jiang X; Lei N; Hu B; Wang X; Li Z; Lin Y; Gou X; Zhu Y; Wang H
    J Endocrinol Invest; 2015 Oct; 38(10):1117-28. PubMed ID: 26036598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical expression and localization of somatostatin receptor subtypes in prostate cancer with neuroendocrine differentiation.
    Morichetti D; Mazzucchelli R; Santinelli A; Stramazzotti D; Lopez-Beltran A; Scarpelli M; Bono AV; Cheng L; Montironi R
    Int J Immunopathol Pharmacol; 2010; 23(2):511-22. PubMed ID: 20646346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Feasibility of experimental BT4C glioma models for somatostatin receptor 2-targeted therapies.
    Kiviniemi A; Gardberg M; Autio A; Li XG; Heuser VD; Liljenbäck H; Käkelä M; Sipilä H; Kurkipuro J; Ylä-Herttuala S; Knuuti J; Minn H; Roivainen A
    Acta Oncol; 2014 Aug; 53(8):1125-34. PubMed ID: 24957558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.